Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial
Respirology · 2023
DOI: 10.1111/resp.14452 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Respirology, 2023. Verfasst von Yoshikazu Inoue und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Centre, National Hospital Organization Kinki-Chuo Chest Medical Centre, Osaka, Japan. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objective In the INBUILD trial in patients with progressive fibrosing interstitial lung diseases (ILDs), nintedanib reduced the rate of decline in forced vital capacity (FVC) with an adverse event profile characterized mainly by gastrointestinal events. We analysed the effects of nintedanib in the subset of Asian subjects.
Methods
Subjects with fibrosing ILDs other than idiopathic pulmonary fibrosis who had shown progression of ILD at any time within the prior 24 months despite management deemed appropriate in clinical practice were randomized to receive nintedanib or placebo. We analysed the rate of decline in FVC (ml/year) over 52 weeks in all Asian subjects and in Asian subjects with a usual interstitial pneumonia (UIP)‐like fibrotic pattern on high‐resolution computed tomography (HRCT).
Results
One hundred sixty‐four subjects in the INBUILD trial were of Asian race. The rate of decline in FVC (ml/year) over 52 weeks in this subgroup was −116.8 in the nintedanib group and −207.9 in the placebo group (difference: 91.0 [95% CI: 8.1, 173.9]; nominal p = 0.03). In Asian subjects with a UIP‐like fibrotic pattern on HRCT, the rate of decline in FVC (ml/year) over 52 weeks was −130.1 in the nintedanib group and −224.2 in the placebo group (difference: 94.1 [5.5, 182.7]; nominal p = 0.04). Adverse events led to treatment discontinuation in 19.0% of the nintedanib group and 13.8% of the placebo group.
Conclusion
In Asian patients with progressive fibrosing ILDs, nintedanib reduced the rate of decline in FVC with adverse events that were manageable for most patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research Centre, National Hospital Organization Kinki-Chuo Chest Medical Centre, Osaka, Japan.
- National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust, and National Heart and Lung Institute, Imperial College, London, UK.
- University of Ulsan College of Medicine, Asan Medical Center, Pulmonary and Critical Care Medicine, Seoul, South Korea.
- Department of Respiratory Medicine, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China.
- Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Kanazawa-ku, Yokohama, Japan.
- Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
ORCID-Profile: Yoshikazu Inoue, Athol U Wells, Masaki Okamoto, Martin Kolb, Kevin K Brown
Zitieren
APA
Inoue, Y., Wells, A. U., Song, J. W., Xu, Z., Kitamura, H., Suda, T., Okamoto, M., Müller, H., Coeck, C., Rohr, K. B., Kolb, M., & Brown, K. K. (2023). Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial. Respirology. https://doi.org/10.1111/resp.14452
Vancouver
Inoue Y, Wells AU, Song JW, Xu Z, Kitamura H, Suda T, et al. Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial. Respirology. 2023. doi:10.1111/resp.14452
BibTeX
@article{Inoue2023,
author = {Inoue, Yoshikazu and Wells, Athol U and Song, Jin Woo and Xu, Zuojun and Kitamura, Hideya and Suda, Takafumi and Okamoto, Masaki and Müller, Heiko and Coeck, Carl and Rohr, Klaus B and Kolb, Martin and Brown, Kevin K},
title = {Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial},
journal = {Respirology},
year = {2023},
doi = {10.1111/resp.14452}
}
EUVIMED